Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CCR9 | P51686 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MLNR | O43193 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4373417 | 0.90 | SMN1; SMN2 (0.52) | HSD17B10ALDH1A1GAASMN1; SMN2MEN1 | |
| SCHEMBL4370076 | 0.88 | CCR9 (0.53) | HSD17B10ALDH1A1GAASMN1; SMN2MEN1 | |
| SCHEMBL4370141 | 0.88 | ALDH1A1 (0.48) | HSD17B10ALDH1A1AKR1C3GAASMN1; SMN2 | |
| SCHEMBL4381242 | 0.86 | GAA (0.50) | HSD17B10ALDH1A1AKR1C3GAASMN1; SMN2 | |
| SCHEMBL4371078 | 0.83 | FLT1 (0.54) | HSD17B10ALDH1A1AKR1C3GAASMN1; SMN2 | |
| SCHEMBL4373358 | 0.82 | ALDH1A1 (0.48) | HSD17B10ALDH1A1AKR1C3GAASMN1; SMN2 | |
| SCHEMBL4370275 | 0.82 | ALDH1A1 (0.52) | HSD17B10ALDH1A1AKR1C3GAASMN1; SMN2 | |
| SCHEMBL4370241 | 0.80 | ALDH1A1 (0.58) | HSD17B10ALDH1A1GAASMN1; SMN2MEN1 | |
| SCHEMBL2651145 | 0.79 | ALDH1A1 (0.73) | HSD17B10ALDH1A1AKR1C3GAASMN1; SMN2 | |
| SCHEMBL4371946 | 0.78 | ALDH1A1 (0.52) | HSD17B10ALDH1A1GAASMN1; SMN2CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625896-B2 | Pyridylsulfonamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-12-01 | — | — | US | claimed |
| EP-1960361-A1 | PYRIDYLSULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTINEOPLASTIC AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | claimed |
| WO-2007059872-A1 | PYRIDYLSULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTINEOPLASTIC AGENTS | F. HOFFMNN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | claimed |
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | HOFFMANN-LA ROCHE INC. | 2007-05-31 | — | — | US | claimed |
| US-7625896-B2 | Pyridylsulfonamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1960361-A1 | PYRIDYLSULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTINEOPLASTIC AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007059872-A1 | PYRIDYLSULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTINEOPLASTIC AGENTS | F. HOFFMNN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | disclosed |
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | HOFFMANN-LA ROCHE INC. | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123513-A1 | 6-thiomorpholin-4-yl-pyridine-3-sulfonic acid 4-chloro-2-methoxy-benzoylamide; ammonium salt of3-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-sulfonic acid 4-chloro-2-methoxy-benzoylamide; anticarcinogenic agent | TPMT, BPNT1, SLC6A3 | HSD17B10 3312/4885ALDH1A1 1180/4885AKR1C3 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.